Dyadic International, Inc. Stock Other OTC
Equities
US26745T1016
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | -58.59% | +5.59% | +79.89% |
Mar. 28 | Transcript : Dyadic International, Inc., 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Dyadic International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 4.2M | Sales 2025 * | 6.1M | Capitalization | 43.56M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -31M | EV / Sales 2024 * | 10.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.14 x |
P/E ratio 2024 * |
-2.26
x | P/E ratio 2025 * |
-1.66
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.91% |
Latest transcript on Dyadic International, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Ping Rawson
DFI | Director of Finance/CFO | 48 | 16-05-31 |
Joseph Hazelton
COO | Chief Operating Officer | 48 | 21-11-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Jack Kaye
BRD | Director/Board Member | 80 | 15-04-30 |
Michael Tarnok
BRD | Director/Board Member | 69 | 14-06-11 |
1st Jan change | Capi. | |
---|---|---|
+2.34% | 42.75B | |
+47.70% | 41.61B | |
+11.94% | 41.34B | |
-12.36% | 26.59B | |
+8.70% | 25.49B | |
-22.96% | 18.12B | |
+30.86% | 12.24B | |
-1.45% | 11.76B | |
+8.48% | 11B |